United States
Print page content Print
Increase text size Decrease text size
Text Size

Fostera PCV MetaStim

Expand All
    • Longest demonstrated PCV2 duration of immunity (DOI) on the market—3 weeks longer than our closet competitor.
    • One-dose vaccine with flexible, 2-dose option to help protect against PCV2.
    • Manufacturing process helps remove extraneous protein that can affect safety and efficacy.
    • Non-viricidal MetaStim adjuvant helps preserve the components and helps elicit a humoral and cell-mediated immune response.1
    • Developed by Zoetis with commitment to best practices and continuous quality improvements.

    REFERENCES
    1. Spickler, AR, Roth JA. Adjuvants in Veterinary Vaccines:
    Modes of Action and Adverse Effects. J Vet Intern Med.
    2003; 17 (3): 273-281.

  • Shake well. Aseptically administer a single 2-mL dose
    intramuscularly to pigs 3 weeks of age or older.
    Fostera PCV MetaStim may also be given as two 1-mL doses
    administered 2 weeks apart.

    • Store at 2°-7°C (35°-45°F).
    • Do not freeze.
    • Use entire contents when first opened.
    • Do not vaccinate within 21 days before slaughter.
    • Contains gentamicin and thimerosal as preservatives.
    • Allergic reactions, although rare, may occur. The antidote
      is epinephrine.

     

  • Fostera PCV MetaStim is the fall-out monovalent PCV fraction
    of Fostera PCV MH. The primary manufacturing difference
    from Fostera PCV is the use of the platform MetaStim.
    The
    data described below highlights the results from the single and
    flexible dose PCV efficacy studies and the field safety study
    conducted using the combination product Fostera PCV MH.
    USDA allows label claims established using the results from
    studies conducted on combination products to be applied to
    the monovalent fall-out products.

    Results of a field, dual-challenge efficacy study comparing
    Fostera PCV MH to competitors demonstrated:

    • Fostera PCV MH single-dose and 2-dose protocols provided
      excellent clinical performance, comparable to competitors.2
    • The group vaccinated once with Fostera PCV MH produced
      more pork and more revenues.3

    Results of a challenge study to evaluate the efficacy of onedose
    Fostera PCV MH:
    4

    • Pigs vaccinated with Fostera PCV MH vs. control pigs:
      −Were aided in preventing PCV2 viremia
      − 91% demonstrated reduction in PCV2 viremia
    • Pigs vaccinated with Fostera PCV MH:
      − 91% demonstrated reduction of PCV2 in lymphoid tissues
      − 100% demonstrated reduction in histiocytic replacement
      following challenge with virulent PCV2.
      −77% reduction in PCV2 antigen detected in tissues

    Results of a challenge study to evaluate the efficacy of twodoses
    of Fostera PCV MH:5

    • Pigs vaccinated with Fostera PCV MH vs. control pigs:
      − Were aided in preventing PCV2 viremia
      − 100% demonstrated reduction in PCV2 viremia
    • Pigs vaccinated with Fostera PCV MH
      − 100% demonstrated reduction of PCV2 in lymphoid tissues
      − 100% demonstrated reduction in histiocytic replacement
      following challenge with virulent PCV2
      − 100% reduction in PCV2 antigen detected in tissues

    REFERENCES

    1.Data on file, Study Report No. B822R-US-13-211, Zoetis Inc.
    2.Data on file, Study Report No. 12ORBIOPORTK01, Zoetis Inc.
    3.Data on file, Study Report No. B822R-US-12-046, Zoetis Inc.
    4.Data on file, Study Report No. B822R-US-11-111, Zoetis Inc.

CONTACT INFORMATION
Technical inquiries should be directed to
Zoetis Inc. Veterinary Services:
(888) 963-8471 (USA) or (800) 461-0917 (Canada)